^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD47 inhibitor

    Related drugs:
    22h
    An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, FBD Biologics Limited | Trial completion date: Aug 2026 --> May 2027 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    HCB101-201: Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=500, Active, not recruiting, FBD Biologics Limited | Recruiting --> Active, not recruiting | N=150 --> 500
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • carboplatin • 5-fluorouracil • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel • Cyramza (ramucirumab) • oxaliplatin • etoposide IV • irinotecan • leucovorin calcium • HCB101
    2d
    HCB101-101: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, FBD Biologics Limited | N=60 --> 80
    Enrollment change
    |
    HCB101
    13d
    Clinical advances in CD47-SIRPα axis-targeted cancer immunotherapy: Mechanisms, strategies, challenges, and future perspectives. (PubMed, Biochem Biophys Res Commun)
    This challenge was underscored by a pivotal setback in the field: the Phase III trial of Magrolimab, the first anti-CD47 therapy to reach this stage, which failed to meet its primary endpoint and ultimately led to the discontinuation of its development program...Furthermore, we summarize the major clinical challenges, including safety concerns, resistance mechanisms, and diagnostic complexities. By synthesizing these key findings, this review provides valuable insights for optimizing future drug design, refining combination regimens, and guiding patient selection strategies, thereby offering a crucial reference for overcoming current limitations and fully realizing the therapeutic potential of this promising axis.
    Review • Journal
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    magrolimab (ONO-7913)
    16d
    IMM0306 in Combination With Lenalidomide VS Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=198, Not yet recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    New P3 trial
    |
    CD20 positive
    |
    lenalidomide • amouravfop alfa (IMM0306)
    30d
    A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. (clinicaltrials.gov)
    P2, N=90, Recruiting, Kahr Bio Australia Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • Fruzaqla (fruquintinib) • DSP-107
    1m
    pH-triggered Mn-ZIF8 nanoreactor enhances tumor immunotherapy by amplifying the cGAS-STING pathway through a self-reinforcing gas-metal synergy strategy. (PubMed, J Nanobiotechnology)
    In this study, we propose a Gas-Metal Synergy Strategy, which integrates immune activation and biosafety, by engineering a pH-responsive manganese-based zeolitic imidazolate framework (named MRPH) nanoplatform co-loaded with the nitric oxide (NO) donor RRX-001...Both in vitro and in vivo studies demonstrate that MRPH significantly enhances gas-amplified metalloimmunotherapy. This work pioneers a low-toxicity paradigm that integrates gas therapy and metal-based immunotherapy, offering a transformative approach to solid tumor immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    nibrozetone (RRx-001)
    2ms
    CD47 expression in solid tumors correlates with phagocytic tumor-associated macrophage gene signature. (PubMed, Front Immunol)
    Investigational agents targeting CD47, such as magrolimab, aim to induce phagocytosis of tumor cells by TAMs...Compared to relatively low CD47 expression in primary CRC tumors, CRC liver metastases had very high CD47 expression. Quantification of TAM signatures and CD47 expression represent key biomarkers to monitor in patient samples during exploration of CD47-blockade agents in the clinic.
    Journal • Gene Signature
    |
    CD47 (CD47 Molecule) • SPP1 (Secreted Phosphoprotein 1)
    |
    magrolimab (ONO-7913)
    2ms
    TQB2928-ALTN-Ib-01: TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=20, Terminated, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=43 --> 20 | Trial completion date: Feb 2026 --> Jun 2025 | Recruiting --> Terminated | Trial primary completion date: Oct 2025 --> Jun 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Focus V (anlotinib)
    2ms
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    New P3 trial
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    2ms
    BAT7104 Injection in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=86, Completed, Bio-Thera Solutions | Recruiting --> Completed | N=42 --> 86
    Trial completion • Enrollment change
    3ms
    A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Kahr Bio Australia Pty Ltd
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • Fruzaqla (fruquintinib) • DSP-107